title: Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
abstract: OBJECTIVE
  The aim of this study was to investigate the feasibility of using quantitative differential echogenicity to monitor the in vivo absorption process of a drug-eluting poly-l-lactic-acid (PLLA) bioabsorbable stent (BVS, Abbott Vascular, Santa Clara, California).
  
  
  BACKGROUND
  A new bioabsorbable, balloon-expanded coronary stent was recently evaluated in a first-in-man study. Little is known about the absorption process in vivo in diseased human coronary arteries.
  
  
  METHODS
  In the ABSORB (Clinical Evaluation of the BVS everolimus eluting stent system) study, 30 patients underwent treatment with the BVS coronary stent system and were examined with intracoronary ultrasound (ICUS) after implantation, at 6 months and at 2-year follow-up. Quantitative ICUS was used to measure dimensional changes, and automated ICUS-based tissue composition software (differential echogenicity) was used to quantify plaque compositional changes over time in the treated regions.
  
  
  RESULTS
  The BVS struts appeared as bright hyperechogenic structures and showed a continuous decrease of their echogenicity over time, most likely due to the polymer degradation process. In 12 patients in whom pre-implantation ICUS was available, at 2 years the percentage-hyperechogenic tissue was close to pre-implantation values, indicating that the absorption process was either completed or the remaining material was no longer differentially echogenic from surrounding tissues.
  
  
  CONCLUSIONS
  Quantitative differential echogenicity is a useful plaque compositional measurement tool. Furthermore, it seems to be valuable for monitoring the absorption process of bioabsorbable coronary stents made of semi-crystalline polymers.
authors.affiliation: Thoraxcenter, Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands. n.Bruining@erasmusmc.nl
authors.forename: Nico
authors.initials: N
authors.lastname: Bruining
authors.forename: Sebastiaan
authors.initials: S
authors.lastname: de Winter
authors.forename: Jos R T C
authors.initials: JR
authors.lastname: Roelandt
authors.forename: Evelyn
authors.initials: E
authors.lastname: Regar
authors.forename: Iddo
authors.initials: I
authors.lastname: Heller
authors.forename: Ron T
authors.initials: RT
authors.lastname: van Domburg
authors.forename: Ronald
authors.initials: R
authors.lastname: Hamers
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Onuma
authors.forename: Darius
authors.initials: D
authors.lastname: Dudek
authors.forename: Mark W I
authors.initials: MW
authors.lastname: Webster
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
authors.forename: John A
authors.initials: JA
authors.lastname: Ormiston
authors.forename: Wai-Fung
authors.initials: WF
authors.lastname: Cheong
authors.forename: Karine
authors.initials: K
authors.lastname: Miquel-Hebert
authors.forename: Susan
authors.initials: S
authors.lastname: Veldhof
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D020341:Absorbable Implants; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D054855:Drug-Eluting Stents; D005060:Europe; D000068338:Everolimus; D005240:Feasibility Studies; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D019344:Lactic Acid / Q000737:chemistry*; D009520:New Zealand; D011091:Polyesters; D011108:Polymers / Q000737:chemistry*; D011237:Predictive Value of Tests; D011474:Prosthesis Design; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012995:Solubility; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: D002317:Cardiovascular Agents; D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide); D000068338:Everolimus; D020123:Sirolimus